Holen Sie sich die Stockscreener-App
12.57
1.45%
0.18
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$12.39
Offen:
$12.5
24-Stunden-Volumen:
1.14M
Relative Volume:
1.22
Marktkapitalisierung:
$1.14B
Einnahmen:
$823.60M
Nettoeinkommen (Verlust:
$-116.00M
KGV:
-9.6692
EPS:
-1.3
Netto-Cashflow:
$-107.30M
1W Leistung:
-8.11%
1M Leistung:
-5.91%
6M Leistung:
-51.60%
1J Leistung:
-38.11%
1-Tages-Spanne:
$12.39
$12.77
1-Wochen-Bereich:
$12.17
$14.31
52-Wochen-Spanne:
$12.17
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Vergleichen Sie MYGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
12.57 | 1.14B | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Myriad Genetics Doubles Cancer Testing Rates with Revolutionary Online Screening Tool - StockTitan
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - MSN
Cancer Biopsy Market Size is Expected to Reach USD 60.92 Billion by 2033, Growing at a CAGR of 7.81%: Straits Research - GlobeNewswire Inc.
Myriad Genetics (NASDAQ:MYGN) Updates FY 2024 Earnings Guidance - MarketBeat
Stephens Reaffirms Equal Weight Rating for Myriad Genetics (NASDAQ:MYGN) - MarketBeat
Myriad Genetics stock hits 52-week low at $12.85 amid market challenges - Investing.com Australia
RSI Alert: Myriad Genetics (MYGN) Now Oversold - Nasdaq
Myriad Genetics: Navigating Through A Setback (NASDAQ:MYGN) - Seeking Alpha
Brokerages Set Myriad Genetics, Inc. (NASDAQ:MYGN) Target Price at $24.27 - MarketBeat
Myriad Genetics sees FY24 adjusted EPS 14c-15c, consensus 13c - MSN
Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month LowWhat's Next? - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases Q4 2024 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Issues FY 2025 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases Q4 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases FY25 Earnings Guidance - MarketBeat
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance - The Manila Times
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial ... - The Bakersfield Californian
Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025 - Marketscreener.com
Myriad Genetics (NASDAQ:MYGN) Stock Price Down 6%Here's What Happened - MarketBeat
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Relationship Genetic Tests Market Report 2024, Featuring - GlobeNewswire
Relationship Genetic Tests Market Report 2024, Featuring Profiles of Laboratory Corporation of America, Quest Diagnostics, Cleveland Clinic, Myriad Genetics, Invitae and More - Yahoo Finance
Myriad Genetics FY2024 EPS Estimate Increased by Scotiabank - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Acquired by Nordea Investment Management AB - MarketBeat
MYGN Stock Gains Following Collaboration With Hannah Storm - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Rating Increased to Buy at StockNews.com - MarketBeat
Myriad Genetics Partners with ESPN's Hannah Storm to Champion Breast Cancer Risk Testing - StockTitan
PARP Inhibitor Biomarkers Market Review 2024 and Forecast 2025-2035: Breast Cancer Applications Lead in Revenue, While Ovarian Cancer Emerges as the Fastest-Growing Opportunity - Yahoo Finance UK
Myriad Genetics and MD Anderson Launch Strategic Partnership to Advance MRD Assays - Zenopa
UPDATEMyriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - StockTitan
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Myriad Genetics to Present at J.P. Morgan Healthcare Conference 2024 with Live Webcast - StockTitan
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued - Simply Wall St
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay - MD Anderson Cancer Center
MD Anderson, Myriad Genetics Partner on Revolutionary Cancer Detection Technology - StockTitan
Myriad Genetics Inc (MYGN) Q2 2024 Earnings: Revenue Surpasses E - GuruFocus.com
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report - The Manila Times
(MYGN) On The My Stocks Page - Stock Traders Daily
Liquid biopsy in cancer diagnostics market is expected to grow at a CAGR of 16.64% by 2030, estimates - EIN News
How to Take Advantage of moves in (MYGN) - Stock Traders Daily
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts - MarketBeat
MYGN Stock Might Gain From the New Recognition of RiskScore Study - MSN
Barclays PLC Increases Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
PARP Inhibitor Biomarkers Market Investment Outlook: Industry - openPR
Pancreatic Cancer Market Analysis 2024: Trends, Growth, and Key - openPR
Myriad Genetics’ RiskScore Study Named One of the Top 10 - GlobeNewswire
Myriad Genetics' Breakthrough Cancer Test Named Top 10 Genomic Advance by Leading Journal - StockTitan
Hereditary Cancer Testing Market: Pioneering Early Detection and Prevention Strategies - openPR
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):